Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre

Br J Haematol. 2021 May;193(4):792-797. doi: 10.1111/bjh.17375. Epub 2021 Mar 9.

Abstract

Myeloproliferative neoplasm-unclassifiable (MPN-U) presents an MPN-type phenotype that fails to meet diagnostic criteria for other MPN variants. Variability in the clinicopathological phenotypes presents many challenges. Amongst a registry cohort of 1512 patients with MPN, 82 with MPN-U were included, with a median (range) age of 49·7 (13-79) years. Albeit heterogeneous, common presentation features included raised lactate dehydrogenase, thrombocytosis and clustered/pleomorphic megakaryocytes on trephine biopsy. Thrombosis was common (21%), necessitating vigilance. The median event-free survival was 11·25 years (95% confidence interval 9·3-not reached), significantly shortened in cases with lower platelet counts (<500 × 109 /l) and a leucocytosis (≥12 × 109 /l) at presentation. Generation of potential MPN-U prognostic scores is required.

Keywords: clinical data; genomics; myeloproliferative neoplasms-unclassifiable; outcome.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Disease-Free Survival
  • Female
  • Hematologic Neoplasms* / blood
  • Hematologic Neoplasms* / mortality
  • Hematologic Neoplasms* / pathology
  • Humans
  • Male
  • Middle Aged
  • Myeloproliferative Disorders* / blood
  • Myeloproliferative Disorders* / mortality
  • Myeloproliferative Disorders* / pathology
  • Retrospective Studies
  • Survival Rate
  • Tertiary Care Centers*
  • United Kingdom